Breast Cancer Awareness
Hormone receptor status A breast cancer diagnosis often comes with a flood of unfamiliar medical terms.
Among the most important are hormone receptor status and HER2 status, which help doctors determine how a cancer is likely to behave and which treatments may be most effective.
Patients may hear terms such as ER-positive, PR-positive or HER2-positive when discussing pathology reports. While the terminology can seem overwhelming, these markers play a critical role in developing a personalized treatment plan.
WHAT DO ER-POSITIVE AND PR-POSITIVE MEAN?
Some breast cancer cells have receptors, or proteins, on their surface that allow them to use hormones as fuel for growth.
ER-positive breast cancers contain receptors for estrogen, while PR-positive cancers contain receptors for progesterone. A tumor may be positive for one hormone receptor, both or neither.
Hormone receptorpositive breast cancers are the most common type of breast cancer. Because these cancers depend on hormones to grow, treatments can be designed to block that process.
Medications such as tamoxifen work by preventing estrogen from attaching to cancer cells. Other treatments, including aromatase inhibitors, reduce the amount of estrogen produced in the body.
Hormone therapy is often prescribed for several years after primary treatment to reduce the risk of recurrence. For many patients, these medications significantly improve long-term outcomes.
Pathology reports typically indicate whether receptors are present and may include the percentage of cancer cells that test positive.
UNDERSTANDING HER2-POSITIVE BREAST CANCER HER2 stands for human epidermal growth factor receptor
2, a protein involved in cell growth.
HER2-positive breast cancers produce excessive amounts of this protein, causing cancer cells to grow and divide more rapidly. In the past, HER2-positive cancers were often associated with poorer outcomes.
Today, however, targeted therapies have dramatically changed the outlook for many patients.
Medications specifically designed to target HER2-positive cancer cells can slow or stop tumor growth while minimizing damage to healthy tissue. These treatments are often used in combination with surgery, chemotherapy or other therapies.
HER2 testing is routinely performed on breast cancer tissue because it helps determine whether these targeted treatments may be beneficial.
HOW THESE RESULTS GUIDE TREATMENT
Hormone receptor status and HER2 status help physicians tailor treatment to the specific biology of a patient’ s cancer.
For example, a cancer that is ER-positive may respond well to hormone-blocking medications, while a HER2-positive cancer may benefit from targeted therapies. Some tumors are both hormone receptor-positive and HER2-positive, requiring a combination of approaches.
Other cancers are classified as triple-negative, meaning they lack estrogen receptors, progesterone receptors and HER2 overexpression. These cancers require different treatment strategies.
Understanding receptor status allows doctors to move beyond a one-size-fits-all approach and select therapies most likely to be effective for each patient. For individuals facing a breast cancer diagnosis, these laboratory findings provide valuable information that helps shape treatment decisions and improve outcomes.
Madison Magazine September-October 2026 27